Eliminating human tuberculosis in the twenty-first century.
Recognizing that tuberculosis (TB) is still the leading cause of human death from a curable infection, the international health community has set ambitious targets for disease control. One target is to eliminate TB by 2050; that is, to cut the annual incidence of new cases to less than 1 per million population. National TB control programmes are working to eliminate TB mainly by intensifying efforts to find and cure patients with active disease. Here, we use mathematical modelling to show that, while most TB patients can be cured with present drug regimens, the 2050 target is far more likely to be achieved with a combination of diagnostics, drugs and vaccines that can detect and treat both latent infection and active disease. We find that the coupling of control methods is particularly effective because treatments for latent infection and active disease act in synergy. This synergistic effect offers new perspectives on the cost-effectiveness of treating latent TB infection and the impact of possible new TB vaccines. Our results should be a stimulus to those who develop, manufacture and implement new technology for TB control, and to their financial donors.
Dye
Christopher
C
HIV/AIDS, Tuberculosis and Malaria, World Health Organization, Avenue Appia 20, 1211 Geneva 27, Switzerland. dyec@who.int
Williams
Brian G
BG
D000995:Antitubercular Agents / Q000627:therapeutic use; D003198:Computer Simulation; D019353:Endemic Diseases; D014943:Global Health; D006801:Humans; D008954:Models, Biological; D014376:Tuberculosis / Q000188:drug therapy / Q000517:prevention & control* / Q000635:transmission
D000995:Antitubercular Agents
Proc Natl Acad Sci U S A. 2000 Jul 5;97(14):8180-5
10859359
Cell. 2006 Feb 24;124(4):683-7
16497578
Nat Rev Immunol. 2005 Oct;5(10):819-26
16200083
Int J Tuberc Lung Dis. 2006 Apr;10(4):460-2
16602414
Epidemiol Infect. 1997 Oct;119(2):183-201
9363017
Lancet. 2006 Mar 18;367(9514):938-40
16546542
Expert Rev Mol Diagn. 2006 May;6(3):413-22
16706743
Lancet. 2006 Apr 8;367(9517):1173-80
16616560
Am J Respir Crit Care Med. 2006 Oct 1;174(7):736-42
16799073
Lancet. 1998 Dec 12;352(9144):1886-91
9863786
Am J Respir Crit Care Med. 2006 Apr 15;173(8):922-6
16474028
Proc Natl Acad Sci U S A. 1998 Nov 10;95(23):13881-6
9811895
Wkly Epidemiol Rec. 2001 Feb 2;76(5):33-9
11218337
Emerg Infect Dis. 2004 Sep;10(9):1523-8
15498151
Lancet. 2006 Mar 18;367(9514):952-5
16546550
Science. 2002 Mar 15;295(5562):2042-6
11896268
Nat Rev Microbiol. 2003 Nov;1(2):97-105
15035039
Int J Tuberc Lung Dis. 2001 Feb;5(2):142-57
11258508
Science. 1996 Jul 26;273(5274):497-500
8662538
Epidemiol Infect. 1998 Oct;121(2):309-24
9825782
Trends Mol Med. 2007 May;13(5):175-82
17418641
Lancet. 2006 Dec 16;368(9553):2142-54
17174706
Lancet Infect Dis. 2003 Jan;3(1):13-21
12505028
N Engl J Med. 2004 May 13;350(20):2060-7
15141044
Nat Med. 1995 Aug;1(8):815-21
7585186
Nat Rev Microbiol. 2005 Aug;3(8):656-62
16012514
Emerg Infect Dis. 2007 Mar;13(3):380-7
17552090
JAMA. 1999 Aug 18;282(7):677-86
10517722